Literature DB >> 20846273

R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer.

Wolf-Rudiger Matull1, Dipok K Dhar, Lakshmana Ayaru, Neomal S Sandanayake, Michael H Chapman, Aruna Dias, John Bridgewater, George J M Webster, Jin J Bong, Brian R Davidson, Stephen P Pereira.   

Abstract

BACKGROUND: There is a need for better management strategies to improve the survival and quality of life in patients with biliary tract cancer (BTC). AIM: To assess prognostic factors for survival in a large, non-selective cohort of patients with BTC.
METHOD: We compared outcomes in 321 patients with a final diagnosis of BTC (cholangiocarcinoma n = 237, gallbladder cancer n = 84) seen in a tertiary referral cancer centre between 1998 and 2007. Survival according to disease stage and treatment category was compared using log-rank testing. Cox's regression analysis was used to determine independent prognostic factors.
RESULTS: Eighty-nine (28%) patients underwent a surgical intervention with curative intent, of whom 38% had R0 resections. Among the 321 patients, 34% were given chemo- and/or radiotherapy, 14% were palliated with photodynamic therapy (PDT) and 37% with biliary drainage procedures alone. The overall median survival was 9 months (3-year survival, 14%). R0-resective surgery conferred the most favourable outcome (3-year survival, 57%). Although patients palliated with PDT had more advanced clinical T-stages, their survival was similar to those treated with attempted curative surgery but who had positive resection margins. On multivariable analysis, treatment modality, serum carbohydrate-associated antigen 19-9, distant metastases and vascular involvement were independent prognostic indicators of survival.
CONCLUSION: In this large UK series of BTC, palliative PDT resulted in survival similar to those with curatively intended R1/R2 resections. Surgery conferred a survival advantage only in patients with R0 resection margins, emphasising the need for accurate pre-operative staging.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2010        PMID: 20846273      PMCID: PMC2997861          DOI: 10.1111/j.1478-3231.2010.02345.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  38 in total

Review 1.  Transplantation for hilar cholangiocarcinoma.

Authors:  Julie K Heimbach; Michael G Haddock; Steven R Alberts; Scott L Nyberg; Michael B Ishitani; Charles B Rosen; Gregory J Gores
Journal:  Liver Transpl       Date:  2004-10       Impact factor: 5.799

2.  Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection.

Authors:  Helmut Witzigmann; Frieder Berr; Ulrike Ringel; Karel Caca; Dirk Uhlmann; Konrad Schoppmeyer; Andrea Tannapfel; Christian Wittekind; Joachim Mossner; Johann Hauss; Marcus Wiedmann
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

3.  Palliation for suspected unresectable hilar cholangiocarcinoma.

Authors:  S Connor; E Barron; D N Redhead; H Ireland; K K Madhavan; R W Parks; O J Garden
Journal:  Eur J Surg Oncol       Date:  2006-12-15       Impact factor: 4.424

4.  Immunoglobulin G4-related sclerosing cholangitis in patients resected for presumed malignant bile duct strictures.

Authors:  D Erdogan; J J Kloek; F J W ten Kate; E A J Rauws; O R C Busch; D J Gouma; T M van Gulik
Journal:  Br J Surg       Date:  2008-06       Impact factor: 6.939

Review 5.  Surgical treatment in proximal bile duct cancer. A single-center experience.

Authors:  R Pichlmayr; A Weimann; J Klempnauer; K J Oldhafer; H Maschek; G Tusch; B Ringe
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

6.  Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach.

Authors:  Emmanuel E Zervos; Dana Osborne; Steven B Goldin; Desiree V Villadolid; Donald P Thometz; Alan Durkin; Larry C Carey; Alexander S Rosemurgy
Journal:  Am J Surg       Date:  2005-11       Impact factor: 2.565

7.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

Review 8.  Current surgical treatment for bile duct cancer.

Authors:  Yasuji Seyama; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

9.  Surgical management and prognostic factors of hilar cholangiocarcinoma: experience with 115 cases in China.

Authors:  Liu Yubin; Fang Chihua; Jian Zhixiang; Ou Jinrui; Liu Zixian; Zheng Jianghua; Lin Ye; Jin Haosheng; Lu Chaomin
Journal:  Ann Surg Oncol       Date:  2008-06-11       Impact factor: 5.344

Review 10.  Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system.

Authors:  E C Burke; W R Jarnagin; S N Hochwald; P W Pisters; Y Fong; L H Blumgart
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

View more
  9 in total

Review 1.  Cholangiocarcinoma--controversies and challenges.

Authors:  Tushar Patel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04       Impact factor: 46.802

2.  The role of macrophage phenotype in vascularization of tissue engineering scaffolds.

Authors:  Kara L Spiller; Rachel R Anfang; Krista J Spiller; Johnathan Ng; Kenneth R Nakazawa; Jeffrey W Daulton; Gordana Vunjak-Novakovic
Journal:  Biomaterials       Date:  2014-02-28       Impact factor: 12.479

3.  How to access photodynamic therapy for bile duct carcinoma.

Authors:  Atsushi Nanashima; Hajime Isomoto; Takafumi Abo; Takashi Nonaka; Tomohito Morisaki; Junichi Arai; Katsunori Takagi; Ken Ohnita; Hiroyuki Shoji; Shigetoshi Urabe; Takemasa Senoo; Goshi Murakami; Takeshi Nagayasu
Journal:  Ann Transl Med       Date:  2014-03

4.  Safety and long term efficacy of porfimer sodium photodynamic therapy in locally advanced biliary tract carcinoma.

Authors:  Stephen P Pereira; Guruprasad P Aithal; Krish Ragunath; John Devlin; Faye Owen; Helen Meadows
Journal:  Photodiagnosis Photodyn Ther       Date:  2012-08-30       Impact factor: 3.631

5.  Photodynamic therapy in unresectable cholangiocarcinoma: not for the uncommitted.

Authors:  Jayant P Talreja; Marisa Degaetani; Kristi Ellen; Timothy Schmitt; Monica Gaidhane; Michel Kahaleh
Journal:  Clin Endosc       Date:  2013-07-31

Review 6.  Application of photodynamic therapy for liver malignancies.

Authors:  Heng Zou; Fusheng Wang; Jiang-Jiao Zhou; Xi Liu; Qing He; Cong Wang; Yan-Wen Zheng; Yu Wen; Li Xiong
Journal:  J Gastrointest Oncol       Date:  2020-04

Review 7.  Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence.

Authors:  S D Gowing; J J Cool-Lartigue; J D Spicer; A J E Seely; L E Ferri
Journal:  Clin Exp Metastasis       Date:  2020-01-23       Impact factor: 5.150

8.  CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma.

Authors:  Sven H Loosen; Christoph Roderburg; Katja L Kauertz; Alexander Koch; Mihael Vucur; Anne T Schneider; Marcel Binnebösel; Tom F Ulmer; Georg Lurje; Wenzel Schoening; Frank Tacke; Christian Trautwein; Thomas Longerich; Cornelis H Dejong; Ulf P Neumann; Tom Luedde
Journal:  Sci Rep       Date:  2017-12-05       Impact factor: 4.379

9.  Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: A meta-analysis.

Authors:  Xujian Huang; Jialin Yang; Jingdong Li; Yongfu Xiong
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.